Back to News
Market Impact: 0.25
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Source: Business Wire
Healthcare & Biotech
New data show twice-yearly lenacapavir achieved nearly twice the one-year persistence of daily oral F/TDF for HIV prevention. The headline provides no absolute persistence rates or additional study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GILD0.70
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Truist raises Vericel stock price target on MACI growth momentum
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)